1. Home
  2. SUPN vs FCF Comparison

SUPN vs FCF Comparison

Compare SUPN & FCF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SUPN
  • FCF
  • Stock Information
  • Founded
  • SUPN 2005
  • FCF 1934
  • Country
  • SUPN United States
  • FCF United States
  • Employees
  • SUPN N/A
  • FCF N/A
  • Industry
  • SUPN Biotechnology: Pharmaceutical Preparations
  • FCF Major Banks
  • Sector
  • SUPN Health Care
  • FCF Finance
  • Exchange
  • SUPN Nasdaq
  • FCF Nasdaq
  • Market Cap
  • SUPN 1.9B
  • FCF 1.7B
  • IPO Year
  • SUPN 2012
  • FCF N/A
  • Fundamental
  • Price
  • SUPN $35.57
  • FCF $18.74
  • Analyst Decision
  • SUPN Hold
  • FCF Hold
  • Analyst Count
  • SUPN 1
  • FCF 5
  • Target Price
  • SUPN $36.00
  • FCF $17.30
  • AVG Volume (30 Days)
  • SUPN 422.4K
  • FCF 580.5K
  • Earning Date
  • SUPN 11-04-2024
  • FCF 10-29-2024
  • Dividend Yield
  • SUPN N/A
  • FCF 2.77%
  • EPS Growth
  • SUPN 130.79
  • FCF N/A
  • EPS
  • SUPN 1.07
  • FCF 1.48
  • Revenue
  • SUPN $651,972,000.00
  • FCF $456,467,000.00
  • Revenue This Year
  • SUPN $7.82
  • FCF N/A
  • Revenue Next Year
  • SUPN N/A
  • FCF $2.15
  • P/E Ratio
  • SUPN $33.25
  • FCF $12.67
  • Revenue Growth
  • SUPN 6.79
  • FCF 1.76
  • 52 Week Low
  • SUPN $25.53
  • FCF $12.41
  • 52 Week High
  • SUPN $39.37
  • FCF $19.51
  • Technical
  • Relative Strength Index (RSI)
  • SUPN 53.46
  • FCF 61.36
  • Support Level
  • SUPN $35.87
  • FCF $18.33
  • Resistance Level
  • SUPN $39.37
  • FCF $19.51
  • Average True Range (ATR)
  • SUPN 1.69
  • FCF 0.56
  • MACD
  • SUPN 0.03
  • FCF 0.16
  • Stochastic Oscillator
  • SUPN 36.03
  • FCF 77.42

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

About FCF First Commonwealth Financial Corporation

First Commonwealth Financial Corp functions in the financial services sector in the United States. Through its subsidiary, it offers a range of consumer and commercial banking services such as personal checking accounts, interest-earning checking accounts, savings accounts, insured money market accounts, investment certificates, fixed & variable rate certificates of deposit, and various kinds of loans. It also provides trust and wealth management services and offers insurance products. The company earns the majority of its revenue through net interest income.

Share on Social Networks: